trending Market Intelligence /marketintelligence/en/news-insights/trending/j4yjqswa5_vxkuqtfixuda2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Patent and Trademark Office OKs MediWound patent for connective tissue disease

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


Patent and Trademark Office OKs MediWound patent for connective tissue disease

The U.S. Patent and Trademark Office granted a patent for MediWound Ltd.'s proprietary injectable bromelain solution, MWPC003, for the treatment of connective tissue diseases.

MWPC003 is an investigational sterile injectable solution containing a mixture of the same pharmaceutical-grade proteolytic enzymes used in the company's burn debridement treatment, Nexobrid, which is approved in Europe and other locations.

The patent provides protection for the drug in the treatment of a variety of connective tissue diseases, such as Dupuytren's contracture, Peyronie's disease and scar treatment, among others.